Moderna Poised to Report Q4 Earnings: Is a Beat in the Cards?

We expect Moderna (MRNA) to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat estimates by 101.59%.The Zacks Consensus Estimate for sales and earnings is pegged at $955.23 million and at a loss of$2.65 per share, respectively. Both metrics indicate a significant decline from the year-ago levels.See the Zacks Earnings Calendar to stay ahead of market-making news.Factors Shaping MRNA’s Upcomi ...